<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53821">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133131</url>
  </required_header>
  <id_info>
    <org_study_id>5172-074</org_study_id>
    <nct_id>NCT02133131</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MK-5172, MK-8742, and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)</brief_title>
  <official_title>A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 and GT3 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of MK-5172A and sofosbuvir (SOF) in treatment-naive participants with
      chronic hepatitis C (HCV) genotype 1 (GT1) or genotype 3 (GT3). The objective is to
      determine the proportion of subjects achieving sustained virologic response (SVR) 12 weeks
      (SVR12) after ending study treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is an open-label, single-center, multiple-arm investigation of MK-5172A (a fixed
      dose combination [FDC] of MK-5172 [100mg] and MK-8742 [50mg]), and SOF 400mg, in
      treatment-naive participants with chronic HCV GT1 or GT3. The impact of study treatment
      regimens of varying duration on SVR12 (defined as HCV ribonucleic acid [RNA] that is lower
      than the limit of quantitation at 12 weeks after the end of study treatment) in cirrhotic
      (C) and non-cirrhotic (NC) participants infected with HCV GT1 or GT3 will be determined
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Percentage of participants achieving SVR12</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants experiencing at least 1 adverse event (AE) on study</measure>
    <time_frame>Up to Week 36</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants discontinuing study therapy due to an AE</measure>
    <time_frame>Up to Week 12</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants achieving SVR4</measure>
    <time_frame>Up to 16 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>GT1:NC MK-5172/MK-8742+SOF 4wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 4 weeks (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1:NC MK-5172/MK-8742+SOF 6wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 6 weeks (n=30)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1:C MK-5172/MK-8742+SOF 6wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 6 weeks (n=20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT1:C MK-5172/MK-8742+SOF 8wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 8 weeks (n=20)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3:NC MK-5172/MK-8742+SOF 8wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 8 weeks (n=15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3:NC MK-5172/MK-8742+SOF 12wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 12 weeks (n=15)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GT3:C MK-5172/MK-8742+SOF 12wk</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK-5172/MK-8742 (100mg/50mg) + SOF 400mg for 12 weeks (n=10)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-5172/MK-8742 FDC</intervention_name>
    <description>FDC tablet (100mg MK-5172/50mg MK-8742), oral once daily (QD)</description>
    <arm_group_label>GT1:NC MK-5172/MK-8742+SOF 4wk</arm_group_label>
    <arm_group_label>GT1:NC MK-5172/MK-8742+SOF 6wk</arm_group_label>
    <arm_group_label>GT1:C MK-5172/MK-8742+SOF 6wk</arm_group_label>
    <arm_group_label>GT1:C MK-5172/MK-8742+SOF 8wk</arm_group_label>
    <arm_group_label>GT3:NC MK-5172/MK-8742+SOF 8wk</arm_group_label>
    <arm_group_label>GT3:NC MK-5172/MK-8742+SOF 12wk</arm_group_label>
    <arm_group_label>GT3:C MK-5172/MK-8742+SOF 12wk</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Sofosbuvir 400mg tablet, oral QD</description>
    <arm_group_label>GT1:NC MK-5172/MK-8742+SOF 4wk</arm_group_label>
    <arm_group_label>GT1:NC MK-5172/MK-8742+SOF 6wk</arm_group_label>
    <arm_group_label>GT1:C MK-5172/MK-8742+SOF 6wk</arm_group_label>
    <arm_group_label>GT1:C MK-5172/MK-8742+SOF 8wk</arm_group_label>
    <arm_group_label>GT3:NC MK-5172/MK-8742+SOF 8wk</arm_group_label>
    <arm_group_label>GT3:NC MK-5172/MK-8742+SOF 12wk</arm_group_label>
    <arm_group_label>GT3:C MK-5172/MK-8742+SOF 12wk</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HCV RNA ≥10,000 IU/mL in peripheral blood at the time of screening

          -  documented chronic HCV GT1 or GT3 infection

          -  negative or positive history of liver cirrhosis based on liver biopsy, Fibroscan, or
             FibroSure ® (Fibrotest®)

          -  treatment naïve to all anti-HCV treatment

        Exclusion Criteria:

          -  has evidence of decompensated liver disease

          -  is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or
             human immunodeficiency virus

          -  history of malignancy ≤5 years prior to signing informed consent, or is under
             evaluation for other active or suspected malignancy

          -  has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of
             hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  has clinically-relevant drug or alcohol abuse within 12 months of screening

          -  has any of the following conditions: organ transplants other than cornea and hair,
             poor venous access that precludes routine peripheral blood sampling, history of
             gastric surgery or malabsorption disorders, or any medical condition requiring, or
             likely to require, chronic systemic administration of corticosteroids during the
             course of the trial

          -  history of chronic hepatitis not caused by HCV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
